Evidence map›Paper›PMID 34542753›Full record

ArticleBulletin of experimental biology and medicine2021

Changes in Bone Marrow Stromal Progenitor Cells in Patients with Hematoblastosis at the Onset of the Disease.

N A Petinati, I N Shipounova, E A Fastova, A U Magomedova, S K Kravchenko, E Yu Chelysheva, O A Shukhov, A G Turkina, N V Sats, N I Drize and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Bulletin of experimental biology and medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

N A PetinatiNational Medical Research Center for Hematology, Ministry of Health of the Russian Federation, Moscow, Russia. loel@mail.ru.
I N ShipounovaNational Medical Research Center for Hematology, Ministry of Health of the Russian Federation, Moscow, Russia.
E A FastovaNational Medical Research Center for Hematology, Ministry of Health of the Russian Federation, Moscow, Russia.
A U MagomedovaNational Medical Research Center for Hematology, Ministry of Health of the Russian Federation, Moscow, Russia.
S K KravchenkoNational Medical Research Center for Hematology, Ministry of Health of the Russian Federation, Moscow, Russia.
E Yu ChelyshevaNational Medical Research Center for Hematology, Ministry of Health of the Russian Federation, Moscow, Russia.
O A ShukhovNational Medical Research Center for Hematology, Ministry of Health of the Russian Federation, Moscow, Russia.
A G TurkinaNational Medical Research Center for Hematology, Ministry of Health of the Russian Federation, Moscow, Russia.
N V SatsNational Medical Research Center for Hematology, Ministry of Health of the Russian Federation, Moscow, Russia.
N I DrizeNational Medical Research Center for Hematology, Ministry of Health of the Russian Federation, Moscow, Russia.
E N ParovichnikovaNational Medical Research Center for Hematology, Ministry of Health of the Russian Federation, Moscow, Russia.
V G SavchenkoNational Medical Research Center for Hematology, Ministry of Health of the Russian Federation, Moscow, Russia.
Ministry of Health of the Russian Federation · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multipotent mesenchymal stromal cells (MSC) are the key regulators of hematopoiesis. We studied changes in MSC characteristics in patients with myeloid leukemia and patients with lymphoproliferative diseases. MSC were obtained from the bone marrow of patients at the time of diagnostic puncture using a standard technique. Their proliferative potential and expression of genes associated with differentiation and regulation of hematopoiesis were studied. The total cell production of MSC in patients with leukemia at the onset of the disease did not differ from that in the group of healthy donors. The relative expression of the IL6, TGFb1 and TGFb2, PPARG genes was similar in all patients. The relative expression of the JAG1, LIF, IGF1, CSF1, IL1b, and IL1bR1 genes in MSC of patients with leukemia was enhanced and the relative expression of SDF1 was unchanged in comparison with MSC from donors. MSC from patients with leukemia were characterized by enhanced relative expression of PDGFRA and PDGFRB, and reduced expression of SOX9. Changes functions of the stromal microenvironment in patients with hemoblastoses attested to the role of stromal cells in the maintenance and spread of tumor cells.

Indexed as

AdultBone MarrowBone Marrow CellsCase-Control StudiesCell CountCell DifferentiationCohort StudiesFemaleHematologic NeoplasmsHematopoiesisHumansLeukemia, Myelogenous, Chronic, BCR-ABL PositiveLeukemia, Myeloid, AcuteLymphoma, Large B-Cell, DiffuseMaleMesenchymal Stem Cellsdiffuse large B-cell lymphomafibroblast colony-forming unitsgene expressionleukemiamultipotent mesenchymal stromal cells

Identifiers

PMID34542753
OpenAlexW3177712856

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.